We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QNCX icon
26
CALL
Quince Therapeutics
QNCX
$21.5M
$13M 0.92%
+711
New +$11.3M
RFL icon
27
PUT
Rafael Holdings
RFL
$103M
$12.7M 0.9%
+419,593
New +$19.3M
SRRA
28
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$12.6M 0.89%
573,380
+28,378
+5% +$568K
MRTX
29
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.4M 0.87%
+70,000
New +$11.3M
IMTX icon
30
Immatics
IMTX
$1.23B
$11.5M 0.81%
883,046
+657,908
+292% +$8.37M
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$11.5M 0.81%
+347,545
New +$19.5M
APLS
32
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$11.4M 0.8%
345,400
+45,400
+15% +$2.55M
MRK icon
33
CALL
Merck
MRK
$322B
$11.3M 0.79%
+150,000
New +$11.4M
RETA
34
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11M 0.78%
+109,600
New +$12.8M
EDIT icon
35
PUT
Editas Medicine
EDIT
$399M
$10.4M 0.74%
+254,100
New +$13.9M
TCON
36
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$10.4M 0.73%
134,556
-1,286
-0.9% -$109K
CCXI
37
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$10.3M 0.72%
600,000
-367,600
-38% -$5.73M
CCXI
38
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$10.3M 0.72%
600,000
+378,800
+171% +$5.9M
MIST icon
39
Milestone Pharmaceuticals
MIST
$129M
$9.99M 0.7%
1,750,043
-230,357
-12% -$1.3M
DRNA
40
CALL
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$9.95M 0.7%
+493,600
New +$13.6M
INBX
41
DELISTED
Inhibrx, Inc. Common Stock
INBX
$9.65M 0.68%
289,850
+281,774
+3,489% +$8.57M
MGNX icon
42
CALL
MacroGenics
MGNX
$233M
$9.34M 0.66%
446,000
+146,000
+49% +$3.52M
BIIB icon
43
Biogen
BIIB
$30.9B
$9.12M 0.64%
32,243
-93,719
-74% -$30.7M
ZGNX
44
CALL
DELISTED
Zogenix, Inc.
ZGNX
$8.97M 0.63%
590,400
-259,600
-31% -$4.06M
ARNA
45
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$8.85M 0.62%
148,700
-1,300
-0.9% -$76.8K
XENE icon
46
CALL
Xenon Pharmaceuticals
XENE
$6.1B
$8.35M 0.59%
546,700
+367,600
+205% +$6.39M
ITCI
47
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.89M 0.56%
211,670
-19,219
-8% -$668K
APLS
48
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$7.68M 0.54%
233,000
-67,000
-22% -$3.76M
PCVX icon
49
Vaxcyte
PCVX
$7.65B
$7.49M 0.53%
295,111
-152,999
-34% -$3.71M
CMPS
50
Compass Pathways
CMPS
$1.47B
$6.85M 0.48%
229,202
+144,139
+169% +$4.84M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.